AAII, Ethypharm morphine deal

Ethypharm (Paris, France) granted aaiPharma (AAII) exclusive U.S. rights to its oral sustained release twice daily morphine sulfate to treat severe pain. The product is marketed in Europe, Canada and Japan, and is in Phase III trials in the U.S. AAII will be responsible for these trials, regulatory submissions and marketing. AAII expects to submit an NDA in 2004. Ethypharm will manufacture the product and will receive milestones and royalties. ...